Alnylam Pharmaceuticals Inc. (ALNY) News
Filter ALNY News Items
ALNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALNY News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ALNY News From Around the Web
Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline GoalsCAMBRIDGE, Mass., January 12, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GAAP operating income profitability, and pipeline goals guidance. |
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 06, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues. |
Exploring High Growth Tech Stocks in the US December 2024The United States market has recently experienced a 2.8% increase over the past week and a substantial 24% climb over the last year, with earnings expected to grow by 15% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to leverage these favorable market conditions. |
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year. |
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, […] |
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and AlnylamSarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog. |
4 Biotech Stocks Most Wall Street Analysts Are Bullish AboutHere, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer StudyCardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients. |
What Makes Alnylam (ALNY) a New Buy StockAlnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year. |